^
    1m
    A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (clinicaltrials.gov)
    P1, N=110, Active, not recruiting, Eli Lilly and Company | Trial primary completion date: Jun 2025 --> Sep 2024
    Trial primary completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    LOXO-260
    8ms
    A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (clinicaltrials.gov)
    P1, N=110, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Jun 2025 | Trial primary completion date: Apr 2026 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    LOXO-260
    over2years
    A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (clinicaltrials.gov)
    P1, N=140, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    LOXO-260
    over2years
    A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (clinicaltrials.gov)
    P1, N=140, Not yet recruiting, Eli Lilly and Company
    New P1 trial
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    LOXO-260
    almost3years
    Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor (clinicaltrials.gov)
    P=N/A, Available, Eli Lilly and Company
    New trial
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    LOXO-260